Table 3 Primary and secondary outcomes—all defined at the level of the individual resident
Outcomes | Scale | Number of repeated measurements |
|---|---|---|
Primary outcome measure | ||
 Number of CNS-active medications (antipsychotics, opioids, benzodiazepines, or antidepressants (including tricyclic antidepressants (TCAs) and trazodone)) | Continuous | Monthly |
Secondary outcome measures | ||
 Benzodiazepine (or z-drug) prescription | ||
  Proportion of days supplied | Continuous | Over the 6-month interval |
  Any prescription of | Binary | Monthly |
  Mean dose dispensed | Continuous | Monthly |
 Antipsychotic prescription | ||
  Proportion of days supplied | Continuous | Over the 6-month interval |
  Any prescription of | Binary | Monthly |
  Mean dose dispensed | Continuous | Monthly |
Presence of 3+ CNS-active medications: antipsychotics, opioids, benzodiazepines, or antidepressants (including TCAs and trazodone) | Binary | Monthly |
Statin—tracer outcome | Continuous | Over the 6-month interval |
Proportion of days supplied | ||